Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

jonzobot

Rank: President [?]

Points: 2527 [?]

Votes: 20 Score: 3.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Toxicity

posted on Nov 02, 2022 03:10PM

It looks like one of the NCI trials has been discontinued due to unacceptable toxicity.

The trial was in Phase 1 for advanced or unresectable solid tumors with RAS alternations or TNBC, in comination with Binimetinib.

https://clinicaltrials.gov/ct2/show/NCT05111561

Another trial was suspended, "to address important protocol updates". Not sure what that means.

https://clinicaltrials.gov/ct2/show/NCT05372640?term=zen-3694&draw=3&rank=12

5 Recommendations

Nov 02, 2022 03:46PM

Nov 02, 2022 03:51PM

Nov 02, 2022 03:53PM

Nov 02, 2022 04:19PM

Nov 02, 2022 04:59PM

tada

Nov 02, 2022 09:26PM

Re: Toxicity

jonzobot

Nov 03, 2022 03:28PM

Re: Toxicity

tada

Nov 03, 2022 04:08PM

Nov 03, 2022 04:50PM

Mar 22, 2023 03:44PM

tada

Mar 24, 2023 02:30PM

Re: Toxicity

Nextblockbuster

Mar 26, 2023 10:12AM

Reply New Message

Back To Forum List View

Please to post a reply